Thursday, February 25, 2021

WHO advises against remdesivir for Covid-19 treatment

WHO says there is 'no evidence based on currently available data that it does improve patient-important outcomes'.

Other News

Covax delivers first vaccine shipment in ‘momentous occasion’

Covax hopes to deliver more than two billion doses in less than a year to ensure 92 poorer countries will receive access to Covid-19 vaccines.

Johnson & Johnson vaccine ‘highly effective’ against severe Covid-19

In large clinical trials, the vaccine efficacy against severe disease was 85.9% in the US, 81.7% in South Africa, and 87.6% in Brazil.

Reaksi kepada kes Malaysiakini tunjukkan politik lebih berkuasa, bukan undang-undang

Keputusan mahkamah perlu dihormati oleh semua pihak tanpa sebarang pertikaian.

Kes baru Covid-19 kembali melebihi angka 3,000

Kes aktif dengan kebolehjangkitan pula berjumlah 30,677.

New cases above 3,000 again as deaths increase by 12

Death toll now at 1,088.

The anti-viral drug remdesivir should not be used to treat Covid-19 patients no matter how severe their illness as it has “no important effect” on survival chances, the World Health Organization (WHO) said Friday.

Scratching one of the few treatments that had shown some initial promise in severe patients, a WHO Guideline Development Group (GDG) of international experts said there was “no evidence based on currently available data that it does improve patient-important outcomes”.

The US, the European Union and other countries have granted temporary approval for the use of remdesivir after initial research showed it may shorten recovery time in some coronavirus patients.

President Donald Trump was treated with remdesivir among other medicines after he tested positive for Covid-19 in October.

Friday’s WHO recommendation was based on four international randomised trials among more than 7,000 patients hospitalised with the virus.

Publishing updated treatment guidance in the BMJ medical journal, the panel acknowledged that their recommendation does not mean that remdesivir has no benefit for patients.

But based on the latest figures, costs and delivery methods, it advised “against administering remdesivir in addition to usual care for the treatment of patients hospitalised with Covid-19, regardless of disease severity”.

Manufacturer Gilead said last month that the drug had boosted 2020 third quarter sales by almost US$900 million.

Initially developed as a treatment for the Ebola virus, remdesivir was found in one study published in May to reduce the length of hospital stays for Covid-19 sufferers from 15 to 11 days on average.

A subsequent WHO pre-print however found the drug “appeared to have little or no effect” on mortality or length of hospitalisation among more than 11,000 hospitalised patients across 30 countries.

Follow us on Telegram for the latest updates: https://t.me/malaysianow

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles

Covax delivers first vaccine shipment in ‘momentous occasion’

Covax hopes to deliver more than two billion doses in less than a year to ensure 92 poorer countries will receive access to Covid-19 vaccines.

Johnson & Johnson vaccine ‘highly effective’ against severe Covid-19

In large clinical trials, the vaccine efficacy against severe disease was 85.9% in the US, 81.7% in South Africa, and 87.6% in Brazil.

New cases above 3,000 again as deaths increase by 12

Death toll now at 1,088.

The scent of a rose and the anguish of post-Covid-19 loss of smell

The loss of the sense of smell and taste drains much of the joy of life for frustrated long-term sufferers.

Muhyiddin, Noor Hisham among first to receive Covid-19 jab

This marks the launch of the National Covid-19 Immunisation Programme, under which about 80% of the population has been targeted with the goal of achieving herd immunity.